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This study shows that an ICP4– replication-deficient herpes simplex virus con-
taining the Moloney murine leukaemia virus LTR fused with the coding se-
quence for the b-galactosidase gene can be used as a very effective vector for
delivering the b-galactosidase reporter gene into the rat brain septum. F344
rats received bilateral stereotaxic injections into the nucleus of the diagonal
band and into the medial septum. The X-gal stain was used to detect the
activity of the expressed b-galactosidase enzyme. The delivered reporter gene
was expressed successfully not only in the neuronal cells of the injected areas
but also in cells that project to the injection area such as cortex cells about
6mm away from the injection sites. Expression was visible at 1, 3 and 9 weeks
following injection. We conclude that this vector can effectively deliver genes
into different regions of the mature mammalian brain and also to areas distant
from the injection site.
Key words: herpes simplex virus, gene therapy, b-galactosidase,
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INTRODUCTION
There are two general approaches to the trans-
fection of genes, the in vivo and the ex vivo [2]. The
in vivo approach is more direct and does not depend
on the success of the cell culture or the subsequent
survival of transplanted cells. However, it does require
a highly efficient method for gene transfer, which is
not an easy procedure, especially in the brain and
other neuronal tissues. The presence of the blood-
brain barrier tends to preclude vascular delivery and
the principally post-mitotic neuronal population pre-
vents the use of retroviruses [36]. The herpes simplex
virus (HSV-1) has the ability to establish life-long la-
tent infections within neurons and may therefore be
considered as a vector for delivering biologically rele-
vant peptides to the nervous system [11]. The herpes
simplex virus does exhibit a neuronal specificity for
establishing a latent infection and during acute in-
fections it has the ability to infect a wide range of cell
types. This fact, coupled with the ability of HSV-1 to
make replication-deficient viruses (ICP4–), opens up
the potential for other therapeutic applications. There-
fore, the use of HSV-1, in particular, as a vector for
delivering and expressing foreign genes within the
nervous system is an attractive option because it is
a neurotrophic virus possessing a sophisticated ge-
netic program that allows it to spend most of its life
cycle within the nervous system [30, 37].
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HSV-1 can enter neurons at the periphery and
travel via axonal transport to the cell bodies of the
sensory ganglia, where it becomes latent [30, 37]. In
addition, normal HSV-1 that can replicate in cells has
the capacity to travel transynaptically to anatomical
locations distant from its original site of infection.
During latency the 152 kb double-stranded DNA
genome of the virus persists as circular episomes
within the nuclei of neurons. The ability of this virus
to co-exist naturally within the nervous system with-
out causing disease or provoking the immune sys-
tem makes it an ideal vector. Key advantages of HSV-1
vectors are that they establish life-long latent infec-
tions within neurons and the genomes exist as mul-
tiple episomal copies per neuron without integra-
tion being known to occur [27]. Because non-repli-
cating HSV-1 recombinants can establish a latent
infection efficiently, safe attenuated vectors for hu-
man gene therapy can be constructed [29]. There is
a great deal of interest in these recombinants con-
taining foreign genes because they can be construct-
ed rapidly and the genome can accept large inserts
of DNA, making the construction of vectors which
express multiple therapeutic genes feasible [12, 14].
To date a number of recombinants have been gen-
erated expressing reporters such as b-galactosidase
[1, 6, 7, 13], glucouronidase [38], tyrosine hydroxy-
lase [8] and nerve growth factor (NGF) [9, 22].
An early experiment using stereotaxic injections
of replication-competent HSV-1 with b-galactosidase-
expressing lacZ reporter gene into the hippocampus
and caudate of the rat brain resulted in limited and
transient viral replication and the establishment of
latency with transient lacZ expression detected in the
dentate gyrus [13]. These early HSV-1 constructs
showed transient high level expression, although this
expression declined rapidly with time. This may be
ideal for some applications. Other applications, on
the other hand, may need long-term expression. This
stable long term expression, however, has been elu-
sive. Since, with the exception of the latency-associ-
ated transcript (LAT) [31], latent infections of HSV-1
are characterised by the absence of viral transcrip-
tion, LAT promoter would be the ideal candidate for
the expression of foreign genes during latency. How-
ever, recombinant viruses containing the genes for
nerve growth factor and b-galactosidase driven by
LAT promoter express b-galactosidase and NGF RNA
at high levels initially but not during the latent in-
fection [24]. Other promoters have been investigat-
ed. The LAP2 (a weaker promoter downstream of
LAT promoter) was shown to be insufficient and
caused a dramatic drop off of expression of some
neuronal housekeeping genes [4]. However, the
Moloney murine leukaemia virus (MoMuLV) LTR has
been demonstrated to afford long-term expression
of b-galactosidase [5, 7] in the context of LAT pro-
moter [20]. This combination of LAT-core promoter
and MoMuLV LTR allows extended expression of
transgenes at high levels within the sensory neurons
of the peripheral nervous system [22], yet only mini-
mal levels of sustained expression within the CNS [5].
Recently the native region of the HSV-1 genome that
may allow sustained expression has been further lo-
calised to an element downstream of LAT termed
LTE (long-term expression) [3, 19]. In addition, there
is evidence that a region upstream of the LAT core
promoter may play a role in enhancing long-term
expression properties [24], and this enhancing ef-
fect may be directed at maintaining the chromatin
HSV-1 containing LAT region in a transcriptionally
permissive conformation [18].
In the non-replicating virus the major viral transac-
tivator gene (infected cell protein 4; ICP4 deleted) and
the resulting virus must be propagated on a helper cell
line that provides the ICP4 gene transfer. This vector
contains the E. coli LacZ gene driven by LAT/MoMuLv
LTR promoter [7].
The data presented from this project not only
evaluated the in vivo expression of the reporter gene
(lacZ) within the rat CNS using the replication-de-
fective HSV-1 viral vector, but also showed that in-
oculation of the septal region with HSV-1 vector pro-
vided gene delivery to several regions of CNS using
a single injection per hemisphere.
MATERIAL AND METHODS
Defective HSV-1 viral vector
The ICP4– replication-deficient virus recombined
with the Moloney murine leukaemia virus LTR down-
stream of HSV LAT promoter were fused with the cod-
ing sequence for the b-gal gene to produce a ICP4-
-LAT/MoMuLVLTR/b-gal cassette. The viruses were pre-
pared and propagated in E5 cells. The final viral prep-
aration was determined by two-step titration analy-
sis on E5 versus RS cells with less than 1 revertant per
5 ¥ 106 plaque forming units (PFU)/ml [5]. The HSV
8117/43 construct utilised in this experiment was
created by deleting the ICP4 gene from the non-rep-
licating HSV vector and inserting the Moloney mu-
rine leukaemia virus (MoMuLV) long terminal region
(LTR) promoter, a gene essential for replication,
which is a transcription unit that replaces both
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copies of the ICP4 gene [7, 21, 29]. Briefly, the con-
struct 8117/43 contains the E. coli lacZ reporter gene
driven by the MoMuLV LTR in place of the deleted
ICP4. It also has a 2.3 kb BstEII deletion in the LAT
(latency associated transcript) 5’ exon/intron region.
The control construct, KD6, contains the same dele-
tion but lacks the lacZ insert. Both KD6 and 8117/43
were propagated on E5 complementing cell line, a gen-
erous gift of N. DeLuca. Infected cells were harvested
and concentrated by centrifugation at 10,000 ¥ g
(30 min at 4oC) and resuspended in 1/100 the origi-
nal cell culture volume in MEM with 10% FBS. The
vector was released from the infected cells and sub-
jected to 2 rounds of freeze-thawing. The stocks
were clarified by centrifugation for 2 minutes at
10,000 ¥ g and the supernatant aliquoted and fro-
zen at –80oC. Stocks were titrated on complement-
ing E5 cells and the number of ICP4+ revertants
determined by passage and titration on RS cells (non-
permissive for ICP4–). All stocks used in this study
had < 1 revertant per 1 ¥ 106 PFU of ICP4– plaques
(as determined on E5 cells).
Animal groups and stereotactic inoculation of
HSV-1 vector to the rat septum (NDB and MS)
Fischer 344 rats (250 g) were randomly divided
into two groups:
— I — HSV-1/b-gal experimental group, injected with
4 ml/site solution of ICP4–LAT/MoMuLVLTR/b-gal
HSV-1 vector;
— II — control groups, injected with 4 ml/site solu-
tion consisting of either viral vector 4 ¥ 106 PFU
HSV-1 lacking the b-galactosidase reporter gene
or glucose control.
All solutions were stereotactically injected (1 ml/min)
to the septal region of the rat CNS using a 100 ml
Hamilton syringe. Each rat was injected bilaterally in
NDB first (2 ml). The needle was then pulled out
1 mm and the rest of the injection solution injected
at MS. Adjustment off the bregma was as follows:
MS and NDB: AP = +0.20, ML = ± 0.30, DV = –7.80
(NDB) –6.80 (MS). All procedures were approved by
the Institutional Animal Care and Use Committee
(IACUC).
Tissue preparation
At different post-injection time points (1, 3, and
9 weeks) the rats were anaesthetised and then per-
fused intracardially with 100 ml of phosphate-buff-
ered saline (PBS, 100 mM phosphate) pH 7.4, fol-
lowed immediately with 150 ml fresh 4% paraform-
aldehyde. Brain tissues were cut into 1 mm sections,
post-fixed for one hour at 4°C with b-gal tissue fixa-
tive (the pH of all the solutions used was above 7.2
to prevent detection of the acidic endogenous b-gal
enzymes). Finally, the post-fixed 1mm sections were
stained with X-gal staining solution for 7 hours. Af-
ter being photographed the tissues were sectioned
into 50 mm slices using a freezing stage microtome
and then mounted on slides, counter-stained with
Eosin Y, dehydrated with alcohol and cover slipped.
PCR detection of HSV-1 DNA
HSV-1 DNA was detected in dissected blocks of
tissue (approx. 1–2 mm2) as follows. After the re-
moval of the brain from the skull, the brain was
chilled to near freezing. With the use of different
razor blades for each section the brain was sectioned
into 1mm coronal slabs. Specific anatomical brain
regions were identified using a brain atlas and were
dissected. The frontal cortex sample (FCX) included
both the parietal and occipital cortex. The BST sam-
ple included the pons and medulla but excluded the
midbrain region. The tissue samples were snap fro-
zen following dissection and the tissue was homoge-
nised in 1.5 ml Eppendorf tubes using a mini bead-
beater (Biospec Products, Bartlesville, OK) in 1.2 ml
of Trizol (Life Technologies, Gaithersburg, MD) with
100 µl of 1.0 mm beads for 30 s (2 ¥ with a 15 s
pause between sets). Chloroform (240 µl) was then
added, followed by vortexing. Samples were incu-
bated for 5 min at room temperature and then mi-
crofuged (10,000 g) for 15 min at 4°C. The DNA was
extracted from the interface with Tris + 0.1% Sarko-
syl (3 ¥ with 140–150 µl). Proteinase K (0.1% µg/µl)
was then added and samples incubated overnight
at 37°C. The next day DNA was extracted with phe-
nol/chloroform/isoamyl followed by chloroform/
/isoamyl. The DNA was then ethanol precipitated
(9 µl 5 M NaCl and 2.5 vol of ethanol) and resus-
pended in 25 ml of dH20. For PCR analysis 5 µl of
a 1:5 dilution of reaction buffer was used. The reac-
tion buffer contained 5 µl of 10 ¥ PCR buffer, 1 µl
cold dNTPs (12.5 mol), 1 µl of primer 1, 1 µl of pri-
mer 2, 40.5 µl dH20, 1 µl hot nucleotide (1:10 dilu-
tion of alpha 32P in dH20) and 0.5 µl Taq. The primers
used were specific for HSV DNA polymerase gene
(Pol): primer 1 = 5’ CAT-CAC-CGA-CCC-GGA-GAG-
-GGA-C and primer 2 = 5’ GGG-CCA-GGC-GCT-TGT-
-TGG-TGT-A. Conditions used for PCR were 1 ¥ 94oC,
68oC, 72oC, 3 min each then 30 ¥ 94oC, 68oC, 72oC,
1 min each. Following PCR samples were electro-
phoresed on a 7.5% acrylamide gel, stained and
scanned. The DNA band was scanned with the
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Molecular Dynamics Phosphorimager and quantified
using ImageQuant software.
RESULTS AND DISCUSSION
The HSV-1 vector can clearly be used to introduce
genes into different regions of the mature mammali-
an brain in vivo [20], with successful transfection of
HSV-1 viral vector into the rat basal forebrain, hip-
pocampus, substantia nigra and ovine corneal endot-
helium previously reported [5, 17, 21, 35]. Here we
show transfection into various regions of the brain
following injections into the septal region using ICP4–
replication-deficient virus containing the Moloney
murine leukaemia virus LTR located downstream of
HSV latency-associated transcript (LAT) promoter
fused with the coding sequence for lacZ gene (ICP4–
LAT/MoMuLVLTR/b-gal cassette). In vivo transgene
expression of b-gal in CNS following bilateral injec-
tion to the septal region using this virus was detected
by the X-gal reaction (Figs. 1A, C). As a control for
either non-transgenic endogenous b-gal or simply
non-specific staining, glucose injections were tested and
showed no staining (Figs. 1B, D). The specificity of the
X-gal staining was confirmed by staining 50 mm thick
sections with anti-b-gal antibody and reflected a sim-
ilar pattern of staining (data not shown). We observed
strong expression of the transferred lacZ gene at the
injected septal areas at one week (Figs. 1A, C) and
three weeks following injection (Fig. 2A). Expression
at week 9 was reduced in comparison with that at
the week 1 and week 3 time points but was still visi-
ble near the needle tracts (Fig. 2B).
In addition to the septal transfection, we de-
tected the expression of b-gal throughout several
other regions of the whole brain, as can be seen in
the serial sections (Fig. 3). Clearly ICP4– replication-
deficient protein was expressed at significant dis-
tances from the injection site (up to 6 mm away) in
numerous regions that have bidirectional connec-
tions with the septum. b-gal activity was detected
in cortical areas including the frontal, insular, or-
bital, piriform, olfactory, and retrosplenial regions.
Some staining can also be seen in the dentate gy-
rus, hypothalamus and raphe. Higher power views
Figure 1. Coronal sections of X-gal stained rat brain following bilateral stereotaxic ICP4–LAT/MoMuL/LTR/b-gal HSV-1 vector injections
(AP = +0.20, ML = ± 0.30, DV = –7.80 to –6.80 mm bregma), shown at the level of the septum. Lower panels (C and D) represent
magnification of the septal region. Panel A and C show strong expression of b-gal activity detected at the injection sites in ventral portion
of the septum. Panels B and D show no b-gal activity detected in the glucose injected control.
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of the stained cells are shown in Figure 4, (20 ¥ cor-
tical areas), Figure 5 (20 ¥ septal area) and Figure 6
(40 ¥ septal area). The medial septum (MS) and
the nucleus of the diagonal band (NDB) are major
parts of the acetylcholinesterase/cholinergic projec-
tion system in CNS [25]. These project extensively
to the hypothalamus and the hypothalamic inner-
vation extends to the medial and lateral preoptic
areas, the anterior, dorsomedial, and ventromedial
nuclei, the lateral hypothalamic area, and the su-
pramammillary and mammillary nuclei. The medial
septum also projects to the ventral tegmental area
and the raphe nuclei [33]. This could partially ex-
plain some of the pattern if transfection can jump
to these cells trans-synaptically. However, this
should not be the case since we are using a replica-
tion-defective virus. The staining pattern in the cor-
tical areas is more likely to be the result of infec-
tion of the axon terminals of the cells projecting to
the septum. The hypothalamus is known to have
extensive projections to the septum [28] and the
hippocampal areas, including CA3, also have pro-
jections to the caudal part of the lateral septal nu-
cleus [26, 34]. The septum does receive glutamin-
ergic input from the frontal cortex [15] and dopam-
inergic input from the raphe [32].
In order to verify whether the b-gal activity detect-
ed in the neuronal perikarya outside the septum was
expressed from the virus harboured by those neurons,
Figure 2. Coronal sections of X-gal stained rat brain following bilateral
stereotaxic injections (AP = +0.20, ML = ± 0.30, DV = –7.80 to
–6.80 mm bregma) shown at the level of the septum at 3 weeks fol-
lowing injection (panel A) and 9 weeks following injection (panel B).
The staining is very robust at 3 weeks but is only visible in the imme-
diate areas around the injection sites at 9 weeks following injection.
Figure 3. 12 consecutive coronal sections (1 mm apart) through the rat brain showing the extent of staining 1 week following bilateral
septal region injections at the level shown in section No. 6. Note that significant staining is visible in the cortical regions in section Nos.
1–7 (+5 to –1 mm bregma).
A
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Figure 4. HSV-1/b-gal expression (1 week following injection) in cortex after injection to septum (20 ¥).
we conducted PCR analysis of the viral DNA in various
brain regions. The detection of the HSV DNA by PCR
was correlated with the histological observation, with
most of the expression found near the injection site in
the septum and significant retrograde migration to the
cortex. Lesser but measurable HSV-1 vector DNA was
detected in the hippocampus, striatum, thalamus, sub-
stantia nigra, brain stem, frontal cortex and tectum,
consistent with the lower amounts of b-gal expression
detected in these regions (Figs. 7A, B).
Figure 5. High power view of successful b-gal gene transfer into the septal neuronal cells using HSV-1 vector.
Successful methods for gene transfer require that
the transgene is taken up by cells, bypass the normal
pathways of lysosomal degradation, be expressed in
the cells (Figs. 4–6), and finally produce long-term sta-
ble expression, either as an independent piece of DNA
or by gaining access to the cell nucleus and incorpo-
rating into host genomic DNA [16]. Interestingly, our
data showed that a single injection provided gene de-
livery to several regions of CNS (Fig. 3) and provided
long-term gene expression at the injection site (Fig. 2).
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A
Figure 7. A. PCR analysis and detection of the viral HSV DNA in various brain regions correlate with the histological observations seen in
Figure 3. B. Most of the expression was near the injection site in the septum (SEP). Significant retrograde migration to the cortex (CX) is
observed. Lesser detection was also noted in the hippocampus (HC), striatum (ST), thalamus (T), substantia nigra (SN) and pons as well
as the medulla parts of the brain stem (BST), frontal cortex (FCX) and tectum (TEC).
B C
Figure 6. Successful expression of b-gal transgene revealed by
X-gal reaction (blue) shown in an individual septal neuron (high
magnification).
Therefore, it is possible to deliver genes in vivo to the
cerebral cortex by injecting a single region of the brain
with HSV-1 viral vector. This may reflect a retrograde
uptake and transport of the non-replicating virus by
the neurons which project to the inoculated area. This
ability of even a replication-incompetent HSV-1 vector
to be efficiently transported in a retrograde fashion
highlights one of its most useful properties for use as
a vector for delivering genes to CNS.
Future lines of study will focus on constructing
viral vectors that express biologically active genes, such
as b-endorphin to treat chronic pain [10], growth fac-
tors to treat degenerative and growth related neuro-
logical diseases [23], and defective growth factor re-
ceptors such as FGFR1(TK–), which we are studying
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for animal models of human diseases. These studies
will be aided by advances in HSV-1 vectors, with im-
provements in both the duration and control of trans-
gene expression.
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